Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | SDCBP | O00560 | 3/20 | 0.38 |
| ▸ | SDC2 | P34741 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448573 | 0.97 | DPP4 (0.41) | NPSR1SLC7A5SMN1; SMN2DPP4FAP | |
| SCHEMBL31129093 | 0.95 | NPSR1 (0.38) | NPSR1SLC7A5SMN1; SMN2DPP4FAP | |
| SCHEMBL29551119 | 0.93 | DPP4 (0.38) | NPSR1SLC7A5SMN1; SMN2DPP4FAP | |
| SCHEMBL30668291 | 0.91 | DPP4 (0.39) | NPSR1SLC7A5SMN1; SMN2DPP4FAP | |
| SCHEMBL29421862 | 0.90 | NPSR1 (0.39) | NPSR1SMN1; SMN2SDCBPSDC2ALDH1A1 | |
| SCHEMBL29349612 | 0.88 | ALDH1A1 (0.42) | NPSR1SMN1; SMN2SDCBPSDC2ALDH1A1 | |
| SCHEMBL34464920 | 0.88 | OPRD1 (0.38) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL30051101 | 0.88 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL29448558 | 0.88 | TERT (0.47) | NPSR1SMN1; SMN2SDCBPSDC2ALDH1A1 | |
| SCHEMBL31588230 | 0.87 | ALDH1A1 (0.43) | SLC7A5DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-12139551-B2 | Anti-IDO antibody and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-11-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | NPSR1 2720/4885SLC7A5 247/4885SMN1; SMN2 4135/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | NPSR1 489/4885SLC7A5 439/4885SMN1; SMN2 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.